West Chester, PA, United States of America

Dashyant Dhanak

This inventor holds 41 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Anti-Cancer Compounds. Top assignees: Smithkline Beecham Corporation, Cytokinetics, Inc., Glaxosmithkline LLC. Active years: 1995-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dashyant Dhanak. Retrieved from https://idiyas.com/inventor/dashyant-dhanak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 41 (Patent Applications = 4)

% Patents Active = 26.8

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.9

ph-index = 12

Forward Citations = 365(Granted Patents)

Location History:

Biggleswade, GB (1995)
King of Prussia, PA (US) (2004 - 2006)
Collegeville, PA (US) (2006 - 2013)
West Chester, PA (US) (1999 - 2014)
Philadelphia, PA (US) (2009 - 2014)

Company Filing History:

30 out of 2,198

Smithkline Beecham Corporation

Smithkline Beecham Intercredit B.v.

patents

where one patent can have more than one assignee

Years Active: 1995-2014

Loading Chart...

Areas of Expertise:

Anti-Cancer Agents

Aurora Kinase Inhibitors

Sulfonamide Derivatives

Imidazole-Benzamide

Azaindole Inhibitors

Pyrrolidine Sulfonamides

Mitotic Kinesin Inhibitors

Urotensin-II Receptor Antagonists

3H-Pyridopyrimidin-4-One

Azetidinone Derivatives

Cellular Proliferation

Atherosclerosis Treatment

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8772507 - Imidazole-benzamide anti-cancer agents (2014-07-08),

2. 8633236 - Compounds, compositions and methods (2014-01-21),

3. 8389723 - Deuterated benzene sulfonamide thiazole compounds (2013-03-05),

4. 8329928 - Compounds, compositions and methods (2012-12-11),

5. 8207340 - Imidazopyridinyl benzamide mitotic kinesin inhibitors (2012-06-26),

6. 8163919 - Imidazopyridinyl benzamide mitotic kinesin inhibitors (2012-04-24),

7. 8119678 - Compounds, compositions and methods (2012-02-21),

8. 7919524 - Compounds, compositions and methods (2011-04-05),

9. 7795448 - Imidazoyl-benzamide anti-cancer agents (2010-09-14),

10. 7629477 - Compounds, compositions and methods (2009-12-08),

11. 7618981 - Imidazopyridinyl-benzamide anti-cancer agents (2009-11-17),

12. 7605266 - Azaindole inhibitors of Aurora kinases (2009-10-20),

13. 7582668 - Imidazoyl-benzamide anti-cancer agents (2009-09-01),

14. 7528137 - Compounds, compositions, and methods (2009-05-05),

15. 7504413 - N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases (2009-03-17),

Title: Innovations by Dashyant Dhanak in Cancer Treatment

Introduction

Dashyant Dhanak, based in West Chester, PA, is a prominent inventor known for his substantial contributions to the field of cancer research. With a remarkable portfolio of 41 patents, Dhanak's innovative work focuses on developing compounds that target cellular proliferative diseases.

Latest Patents

Dhanak's latest patents include groundbreaking discoveries such as Imidazole-benzamide anti-cancer agents, which are compounds aimed at treating cellular proliferative diseases and disorders. These agents operate by modulating the activity of one or more mitotic kinesins. Additionally, he has patented compounds, compositions, and methods that are useful for addressing cellular proliferative diseases by modulating the activity of KSP.

Career Highlights

Throughout his career, Dashyant Dhanak has worked with notable organizations, including SmithKline Beecham Corporation and Cytokinetics, Inc. His work at these companies has significantly influenced advancements in the pharmaceutical industry, particularly in the development of cancer therapies.

Collaborations

Dhanak has collaborated with esteemed colleagues such as Steven David Knight and Gustave Bergnes. These partnerships have allowed for the sharing of expertise and ideas, further fostering innovation in the field of medicinal chemistry.

Conclusion

Dashyant Dhanak exemplifies the essence of innovation in cancer treatment through his extensive work and numerous patents. His ability to develop effective compounds embodies the spirit of research and dedication in addressing some of the most challenging medical conditions.

Profile summary based on public USPTO records.